Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ComplianceQuest and Zolon PCS Selected to Modernize U.S. Food and Drug Administration (FDA) Enterprise Quality Management System6.10.2026 18:00:00 CEST | Press release
TAMPA, FL / ACCESS Newswire / October 6, 2026 / ComplianceQuest, a leading provider of AI-powered connected Quality, Risk and Compliance (QRC) systems, and Zolon PCS, a provider of secure, mission-focused IT services to federal agencies, today announced that the U.S. Food and Drug Administration (FDA) will modernize its enterprise quality management operations on the ComplianceQuest platform. The initiative will be delivered under the FDA Cloud Quality Management System Blanket Purchase Agreement (BPA), a five-year agreement awarded to Zolon PCS as prime contractor, with ComplianceQuest as its platform partner. Together, ComplianceQuest and Zolon PCS will help FDA implement a modern, secure, AI-enabled quality management solution built on the Salesforce FedRAMP Government Cloud platform. The solution is designed to strengthen compliance, improve consistency, streamline quality processes, and deliver greater insight across FDA's centers and offices. The initiative will focus on four pri
Stagwell Launches New Global Media Agency, Stagwell Media6.10.2026 15:45:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / October 6, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the launch of Stagwell Media, its global media agency that delivers performance built to unlock ambition. The name Stagwell Media marks a new approach to media building on the Assembly agency, bringing together its performance heritage and ecosystem expertise while debuting a new agile, integrated model powered by next generation agentic technology, Stagwell's Machine OS. Designed for the rapidly changing media landscape, Stagwell Media delivers performance with the speed, flexibility and intelligence required to succeed in a world where brands must engage priority audiences while influencing the agentic systems that shape discovery, recommendation and activation.By transforming media into a more connected and adaptive growth engine, the agency empowers brands to unlock greater ambition and drive stronger business results. "The
Valsoft Corporation Announces Acquisition of the Firebrand Group Collection of Companies6.10.2026 14:50:00 CEST | Press release
MONTRÉAL, QC / ACCESS Newswire / October 6, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Montreal-based company specializing in the acquisition and development of vertical market software businesses, today announced the acquisition of Firebrand Technologies ("Firebrand"), NetGalley LLC ("NetGalley"), and Supadu Ltd ("Supadu"), together known as the Firebrand Group, a global collection of companies providing leading software and services that help publishers succeed. Valsoft acquired the Firebrand Group from Media Do International, the US-based subsidiary of MEDIA DO Ltd., in Japan. Founded in 1987 and headquartered in Newburyport, Massachusetts, Firebrand Technologies provides title management and metadata software publishers use to plan, manage, and distribute book data to retailers and trading partners around the world. Its flagship platform, Title Management Enterprise, runs the publishing workflow from acquisition through publication, keeping schedules, rights, costs,
U.S. Polo Assn. Celebrates an Outstanding 2026 European Polo Season6.10.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / October 6, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), supported several major sports events across Europe during the 2026 summer season, reinforcing the brand's authentic connection to the sport across the continent. U.S. Polo Assn. served as the Official Apparel and Jersey Sponsor for multiple events, including:55th Sotogrande International Polo Tournament at Ayala Polo Club in Sotogrande, Spain;Barnes French Open at Polo Club de Chantilly in France;Engel & Völkers Berlin Maifeld Polo Cup in Germany;Museumplein Polo Amsterdam in the Netherlands; Barnes French Open Winners, Kazak, on stage with trophy at Polo Club de Chantilly in France Across these partnerships, U.S. Polo Assn. outfitted players, umpires, and event staff while supporting competition ranging from historic high-goal championships in iconic venues throughout the region. "U.S. Polo Assn.'s presence across Europe reflects both the
Synexis and Customate Collaborate to Advance Continuous Indoor Pathogen Control for the U.K. Poultry Industry5.10.2026 22:10:00 CEST | Press release
OVERLAND PARK, KS AND YORKSHIRE, ENGLAND / ACCESS Newswire / October 5, 2026 / Synexis®, LLC, the leader in touchless, continuous pathogen control technology, has announced a strategic collaboration with Customate Solutions, a family-owned engineering company and trusted provider of innovative manufacturing solutions with deep expertise across the poultry industry. The collaboration will bring Synexis patented DHP® technology to poultry producers throughout the United Kingdom and Ireland, helping hatcheries, poultry farms, processing facilities, and related operations strengthen indoor pathogen control while supporting modern biosecurity strategies. Poultry producers today face increasing pressure to maximize healthy hatch rates, improve chick quality, and strengthen biosecurity while reducing operational risk. Bacterial contamination on hatching eggs and throughout hatchery environments can directly impact hatchability, flock health, and production performance, making effective pathog
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom